At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 588 enrolled
Drug / intervention
Olmesartan +2 moredrug
Likely dose
Olmesartan 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating Olmesartan, Placebo, and 1 other intervention for Essential Hypertension. Completed, enrolled 588 participants across 79 sites in 7 countries.
Detailed Summary
The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesChina, Hong Kong, Japan, Philippines, South Korea, Taiwan, Thailand
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartAug 2012
Primary CompletionJul 2013
TodayJul 2026
First PostedJun 8, 2012
Enrollment StartAug 1, 2012
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.1 years ago
Interventions
Olmesartandrug
10 mg, 20 mg, 40 mg capsules
Placebodrug
Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
LCZ696drug
100 mg, 200 mg tablets